Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 18Neoplasms 16Prostatic Neoplasms 12Neoplasm Metastasis 10Pain 9Colorectal Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 8Polycystic Ovary Syndrome 7Leiomyoma 6Anemia 5Skin Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia 4Carcinoma, Renal Cell 4Recurrence 3Melanoma 3Liver Neoplasms 3Kidney Neoplasms 3Keratosis, Actinic 3Insulin Resistance 3Carcinoma, Hepatocellular 3Cancer Pain 3Brain Neoplasms 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2

Interventions

Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Terminated × Breakthrough Pain × Clear all
NCT00842829 2012-10-01

Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 4 Terminated
330 enrolled 32 charts

Cancer Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡